Commitment to patients

For us, meaningful engagement and cooperation with the rare disease community are essential. We are in a position to improve health globally for a number of small and often overlooked patient populations.

One of the two main aspects of our sustainability strategy is to maintain our commitment to patients. This will be achieved by supporting the rare disease community, ensuring reliable and secure access to medicines, giving a voice to patients, and enabling connectedness. The strategy also reflects our ambition and commitment to reach more people with novel and transformative medicines in areas of high unmet medical need through geographical expansion.

Expanded access to treatment

Our growth and expansion strategy helps bring medicines to new markets and adds indications, which allows more patients to access medicine. We also have a partnership strategy to serve currently underserved markets. To increase access to medicine, we work with communities to increase patient access through the established healthcare system. We support home nursing and medicine delivery programmes, telemedicine, patient navigation tools, culturally and linguistically adapted tools as well as adherence programmes.

Learn more about how we work to expand access to treatment.

Community engagement

We engage with patient organisations and networks in clinical development to design clinical studies and create solutions with and for the patient community. By embedding experience and input from patient communities, we help to ensure that future medicines help address patient needs. 

The company continued its partnership with the European Patients’ Academy on Therapeutic Innovation (EUPATI) and Patient Focused Medicine Development (PFMD) to support the education and involvement of the patient community in clinical studies. By the end of 2022, it had established four international patient councils to advise on early clinical development.

Learn more about how we work to apply patient centricity in all our ways of working.